Lombard Medical Technologies, a medical device company focused on devices for the US$1.1 billion abdominal aortic aneurysm repair market, announced that, its flagship product, the Aorfix endovascular stent graft, is now the third most widely used aortic stent graft in the UK, according to data published by the independent market researcher BIBA Medical Ltd.
The data shows that the market share held by Aorfix grew by approximately 85% last year and it accounted for nearly 9% of the UK abdominal aortic aneurysm stent graft market in 2010.
The significant growth in the adoption of Aorfix by leading clinicians has been driven by the publication of substantial supportive clinical research, evidencing the superiority of Lombard Medical’s product in difficult to treat cases and its exclusive market position as the only endovascular stent graft approved in Europe to treat complex anatomies with angulations up to 90°.
It also reflects the strategic decision to focus sales and marketing resources on Europe’s five largest markets, led initially by the UK and Germany.
“We are investing heavily in building up the sales and marketing behind Aorfix and the sharp rise in the UK market share in 2010 shows that our strategy is working,” said Simon Hubbert, chief executive officer, Lombard Medical. “The clear benefits of Aorfix in difficult to treat aortic aneurysms are being recognised by specialist clinicians in the UK and other markets, and we look forward to further significant growth in Europe,” he added.
The single use stent graft is used to treat aortic, aortoiliac and iliac aneurysms. Approximately 2,000 patients worldwide have been treated with Aorfix and growing body of clinical evidence confirms that Aorfix reduces EVAR complications such as proximal endoleaks, graft migration and iliac occlusion in patients with both standard and complex abdominal aortic aneurysm anatomies.
Aorfix is currently licensed for use in Europe, Russia and Brazil. Recruitment of a pivotal US trial is almost complete, with FDA approval to market the product in the USA expected by the end of 2011.